Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
<p>Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment</p>
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Drugi avtorji: | , , , , , , , , , , , , , , , , |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Označite
Brez oznak, prvi označite!
|